HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
HLS-表面引发血栓形成的因子 XII 抑制剂
基本信息
- 批准号:9324070
- 负责人:
- 金额:$ 99.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdverse effectsAntibodiesAnticoagulantsAnticoagulationAntithrombinsBindingBleeding time procedureBloodBlood PlateletsBlood VesselsBlood coagulationBlood flowBusinessesCardiac Surgery proceduresCardiopulmonary BypassCell LineChemistryClinical ResearchClinical TrialsCollaborationsComplement 5aCritical IllnessDataDepositionDevelopmentDevicesDoseDose-LimitingDrug CompoundingDrug KineticsEffectivenessEligibility DeterminationEquilibriumExperimental ModelsExtracorporeal Membrane OxygenationFactor XIIFactor XII DeficiencyFactor XaFibrinFibrinolytic AgentsGenerationsGuidelinesHealthcareHemorrhageHemostatic AgentsHemostatic functionHeparinHumanHybridomasImmunizeIn VitroInjectableInterruptionInterventionInvestigational DrugsInvestigational New Drug ApplicationKnockout MiceLeadLettersLeukocyte ElastaseLifeLinkLungMammalsMedicalMembraneModelingMolecularMonoclonal AntibodiesMusNational Heart, Lung, and Blood InstitutePapioPathologicPathway interactionsPatientsPerfusionPharmaceutical PreparationsPharmacodynamicsPharmacologyPhasePlatelet ActivationPrimatesProceduresProcessProsthesisPublishingPumpQuality ControlRecombinantsResearchResearch ContractsResidual stateRiskSafetySavingsSmall Business Innovation Research GrantSterilitySurfaceTNFSF5 geneTherapeuticTherapeutic IndexTherapeutic antibodiesThrombinThrombosisThrombusToxic effectToxicity TestsToxicologyVascular GraftVial deviceWorkantigen bindingbasecell bankdrug candidateefficacy studyexperienceexperimental studyhumanized antibodyimplantationimprovedin vitro activityin vitro testingindustry partnerinflammatory markerinhibitor/antagonistinnovationinterestmurine monoclonal antibodynovel therapeuticspreclinical toxicitypreventproduct developmentpublic health relevancesafety studystability testingsuccessventricular assist device
项目摘要
DESCRIPTION (provided by applicant): This Phase I/II Fast-Track application is being re-submitted under the NHLBI Small Business Topics of Special Interest for Fiscal Year 2016 (HLS16-04). Certain life-saving interventions such as cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), or ventricular assist device (VAD) pump require the use of high dose heparin to maintain blood flow through the devices and/or to prevent downstream thromboembolic complications. Several other invasive vascular procedures also utilize profound temporal anticoagulation, such as during and after prosthetic vascular graft implantation. Unfortunately, antithrombotic agents such as heparin inadvertently target vital hemostatic molecular mechanisms and can produce severe dose-limiting hemorrhagic toxicity. Consequently, the level of anticoagulation must be limited to balance the risk of bleeding with thrombosis. As a result, thrombotic complications can be frequent and devastating. Our recent studies suggest that coagulation factor XII (FXII) contributes to the progression of thrombosis, and thereby is a potential target for a new class of antithrombotic drugs. Since data suggests that FXII does not contribute to hemostasis, and FXII deficiency is an asymptomatic condition in mammals, FXII inhibition is unlikely to have significant adverse effects. We have generated a proprietary murine monoclonal antibody, 15H8, against human FXII that was created by immunizing FXII knockout mice, and verified its anticoagulant and antithrombotic effects in preliminary primate experiments. This proposed Phase I/II Fast-Track project will initiate the commercial development of a recombinant humanized version of 15H8 (rh15H8), a product candidate that could be used as a stand alone or as an adjuvant anticoagulant to increase the antithrombotic efficacy of heparin without further increasing heparin-associated bleeding risks. The Specific Aims for this project that will be necessary to support 15H8 development towards an investigational new drug (IND) application are to: 1) Evaluate the antithrombotic effect of the murine anti-FXII antibody (15H8) in a primate model of experimental extracorporeal membrane oxygenation (ECMO), 2) Determine the activity and efficacy of recombinant humanized 15H8 (rh15H8), and 3) Manufacture rh15H8 for use in GLP toxicity studies. The rh15H8 approach represents a fundamentally new therapeutic anticoagulation concept since FXII inhibition is expected to reduce the formation of contact-initiated blood clots in synthetic grafts and extracorporeal devices without a detrimental effect on residual bleeding control in critically ill,
anticoagulated patients. Success of this project and reaching our critical milestones will lead directly to the next stage of product development that will consist of GLP toxicity and stability studies, IND preparation and filing, followed by the initiation of phase 1 first- in-human safety studies of our innovative antithrombotic drug candidate.
说明(由申请人提供):此 I/II 期快速通道申请正在根据 2016 财年 NHLBI 小企业特别关注主题 (HLS16-04) 某些挽救生命的干预措施(例如心肺搭桥)重新提交。 CPB)、体外膜肺氧合(ECMO)或心室辅助装置(VAD)泵需要使用高剂量肝素来维持通过装置的血流和/或一些其他侵入性血管手术也利用深度暂时抗凝,例如在人工血管移植物植入期间和之后,不幸的是,肝素等抗血栓药物无意中针对重要的止血分子机制,并可能产生严重的剂量限制性出血毒性。试验中,必须限制抗凝水平以平衡出血与血栓形成的风险,因此,我们最近的研究表明,血栓并发症可能很频繁且具有破坏性。凝血因子 XII (FXII) 有助于血栓形成的进展,因此是一类新型抗血栓药物的潜在靶点,因为数据表明 FXII 不有助于止血,并且 FXII 缺乏是哺乳动物的一种无症状病症,因此抑制 FXII 是一种有效的治疗方法。我们已经生成了一种针对人 FXII 的专有鼠单克隆抗体 15H8,该抗体是通过免疫 FXII 敲除而产生的。小鼠,并在初步灵长类动物实验中验证了其抗凝血和抗血栓作用。该拟议的 I/II 期快速通道项目将启动 15H8 (rh15H8) 的重组人源化版本的商业开发,这是一种可用作标准的候选产品。单独或作为辅助抗凝剂,以提高肝素的抗血栓功效,而不进一步增加肝素相关的出血风险。支持 15H8 开发以实现研究性新药 (IND) 应用的必要条件是:1) 在实验性体外膜氧合 (ECMO) 灵长类动物模型中评估鼠抗 FXII 抗体 (15H8) 的抗血栓形成作用,2) 确定重组人源化 15H8 (rh15H8) 的活性和功效,以及 3) 制造用于 GLP 毒性的 rh15H8 rh15H8 方法代表了一种全新的抗凝治疗概念,因为 FXII 抑制有望减少合成移植物和体外装置中接触引发的血栓形成,而不会影响危重患者的残余出血控制。
该项目的成功并达到我们的关键里程碑将直接进入下一阶段的产品开发,其中包括 GLP 毒性和稳定性研究、IND 准备和备案,然后启动第一阶段人体安全性。我们的创新抗血栓候选药物的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erik Ian Tucker其他文献
Anticorps monoclonaux anti-facteur xi et leurs procédés d'utilisation
Anticorps monoclonaux anti-facteur xi 和 leurs procédés dutilization
- DOI:
10.1016/j.resp.2020.103484 - 发表时间:
2008-11-21 - 期刊:
- 影响因子:2.3
- 作者:
A. Gruber;Erik Ian Tucker;S. R. Hanson;D. Gailani - 通讯作者:
D. Gailani
Erik Ian Tucker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erik Ian Tucker', 18)}}的其他基金
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10616494 - 财政年份:2019
- 资助金额:
$ 99.88万 - 项目类别:
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10378696 - 财政年份:2019
- 资助金额:
$ 99.88万 - 项目类别:
Antithrombotic Protein C Activator for Hemodialysis
用于血液透析的抗血栓蛋白 C 激活剂
- 批准号:
10213549 - 财政年份:2019
- 资助金额:
$ 99.88万 - 项目类别:
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
HLS-表面引发血栓形成的因子 XII 抑制剂
- 批准号:
9137247 - 财政年份:2016
- 资助金额:
$ 99.88万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
9301688 - 财政年份:2013
- 资助金额:
$ 99.88万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8456004 - 财政年份:2013
- 资助金额:
$ 99.88万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8641021 - 财政年份:2013
- 资助金额:
$ 99.88万 - 项目类别:
Therapeutic Protein C Activator for Myocardial Ischemia
治疗心肌缺血的蛋白 C 激活剂
- 批准号:
8826804 - 财政年份:2013
- 资助金额:
$ 99.88万 - 项目类别:
相似国自然基金
基于纳米铝乳剂和模式识别受体激动剂的复合型佐剂研究
- 批准号:82341043
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
茯苓多糖-蜂窝状氧化锰纳米粒的佐剂活性及作用机制研究
- 批准号:32302914
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
可注射大孔明胶支架负载易被吞噬和自佐剂的肿瘤细胞建立治疗性肿瘤疫苗激活T细胞免疫响应
- 批准号:32371395
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
多级改造的工程化外泌体自佐剂疫苗平台实现鼻上皮细胞感染拟态和粘膜递送的研究
- 批准号:32371440
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
具有免疫佐剂活性的复杂三萜皂苷QS-21类化合物的高效合成研究
- 批准号:22377038
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Multidomain Peptide Hydrogels as a Therapeutic Delivery Platform for Cancer Treatment
多域肽水凝胶作为癌症治疗的治疗传递平台
- 批准号:
10743144 - 财政年份:2023
- 资助金额:
$ 99.88万 - 项目类别:
A Mouse Model to Test the Effects of Gender-affirming Hormone Therapy on HIV Vaccine-induced Immune Responses
测试性别肯定激素疗法对 HIV 疫苗诱导的免疫反应影响的小鼠模型
- 批准号:
10748892 - 财政年份:2023
- 资助金额:
$ 99.88万 - 项目类别:
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
开发针对胰腺癌的条件装甲 CAR 巨噬细胞疗法
- 批准号:
10710883 - 财政年份:2023
- 资助金额:
$ 99.88万 - 项目类别:
Development of contrast agents to facilitate image-guided surgery
开发造影剂以促进图像引导手术
- 批准号:
10810184 - 财政年份:2023
- 资助金额:
$ 99.88万 - 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
- 批准号:
10589192 - 财政年份:2023
- 资助金额:
$ 99.88万 - 项目类别: